RxDoctor Payments DataLook up a doctor →

Mohamed Elhassan, MD

Hospitalist · The Woodlands, TXNPI 1669797940

Payments from drug & device makers

$11,449in general payments, 2019–2025

Across 598 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Corcept Therapeutics$715
  • Amgen$681
  • Boehringer Ingelheim$519
  • Sanofi-aventis U.S. LLC$392
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$11,436100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,449 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas

Medicare billing

Part B allowed, 2024
$125,308
Medicare patients
414
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide313$563,380
JardianceEmpagliflozin235$281,030
MounjaroTirzepatide113$204,664
TrulicityDulaglutide101$157,640
FarxigaDapagliflozin Propanediol113$151,973
Tresiba Flextouch U-100Insulin Degludec106$89,236
Tresiba Flextouch U-200Insulin Degludec35$75,824
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$75,303
Synjardy XrEmpagliflozin/Metformin Hcl52$67,931
Humulin R U-500 KwikpenInsulin Regular, Human35$58,124
JanuviaSitagliptin Phosphate47$43,071
TradjentaLinagliptin31$37,796
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$26,191
Fiasp FlextouchInsulin Aspart (Niacinamide)14$19,502
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$19,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,404$568,177328 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$519$386,756318 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$1,311$364,084229 claims
AstraZenecaFarxiga$352$151,973113 claims
MerckJanuvia$20$43,07147 claims
AbbVieSynthroid$294$3,45940 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$67$3,382322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 hospitalist providers in Texas.

Other hospitalist in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →